Postmarketing surveillance of enalapril. II: Investigation of the potential role of enalapril in deaths with renal failure.

The possibility that enalapril might damage renal function was investigated in 1098 deaths recorded in a prescription-event monitoring study. Case notes for 913 patients were examined. In seventy five there was a rise in the urea or creatinine concentration of 50% or more above pretreatment values. Enalapril appeared to have contributed to a decline in renal function and subsequent death in 10 of these patients. Several characteristics were identified among these patients, including old age, the use of high dose or potassium sparing diuretics, and pre-existing renal disease. Adding a non-steroidal anti-inflammatory drug was also associated with a deterioration in patients with previously stable renal function. No death was encountered of a patient with uncomplicated hypertension. Enalapril infrequently contributed to a substantial decline in renal function in certain vulnerable patients, especially those receiving other drugs known to be capable of adversely affecting renal function. Awareness of the characteristics of these patients and of their concomitant treatment may serve to reduce the risk.

[1]  W. Inman,et al.  Postmarketing surveillance of enalapril. I: Results of prescription-event monitoring. , 1988, BMJ.

[2]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[3]  D. Brown,et al.  Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice. , 1987, The Journal of the Royal College of General Practitioners.

[4]  Renal syndromes associated with non-steroidal anti-inflammatory drugs , 1984 .

[5]  Y. Sugiyama,et al.  Binding of glutathione by rat liver cytosol. , 1984, Pharmacology.

[6]  E. Freis,et al.  Low-dose captopril for the treatment of mild to moderate hypertension. , 1983, Hypertension.

[7]  L. Horowitz,et al.  Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity. , 1983, Journal of the American College of Cardiology.

[8]  M. Schreiber,et al.  Renal failure associated with captopril. , 1983, JAMA.

[9]  W. Blythe Captopril and renal autoregulation. , 1983, The New England journal of medicine.

[10]  N. Hollenberg Renal response to angiotensin-converting enzyme inhibition. , 1982, The American journal of cardiology.

[11]  M. Vallotton,et al.  Reversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjects. , 1982, Annals of internal medicine.

[12]  E Scowen,et al.  Committee on Safety of Medicines. , 1978, British journal of anaesthesia.

[13]  K. Lynn,et al.  Spironolactone-associated aggravation of renal functional impairment. , 1976, The New Zealand medical journal.